CLYM Stock Analysis: Buy, Sell, or Hold?
CLYM - Climb Bio, Inc. Common Stock
$10.44
-0.76 (-6.79%)
▼
5d:
-12.71%
30d:
+7.74%
90d:
+43.41%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When CLYM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CLYM is down 12.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CLYM is down 12.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CLYM is currently trading at $10.44, which is considered slightly high relative to its 30-day fair value range of $9.61 to $11.69.
Technical Outlook: Technically, CLYM is in a strong uptrend. Immediate support is located at $9.71, while resistance sits at $12.20. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.77 (+89.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLYM is in a strong uptrend. Immediate support is located at $9.71, while resistance sits at $12.20. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.77 (+89.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$9.61 -
$11.69
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.6%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.8%)
- BULLISH: Trading 89.4% below Wall St target ($19.77)
- WARNING: Recommendation downgraded due to -12.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$9.61 -
$11.69
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$9.71
Resistance Level
$12.20
Current Trend
Strong Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.30
Wall Street Target
$19.77
(+89.4%)
Share & Embed Analysis
Last updated: June 04, 2026 7:24 AM ET
Data refreshes hourly during market hours. Next update: 8:24 AM
Data refreshes hourly during market hours. Next update: 8:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLYM showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ra Capital Management, L…
BUY
7111 shares
2026-01-05
Ra Capital Management, L…
BUY
101462 shares
2025-12-12
Ra Capital Management, L…
BUY
213099 shares
2025-12-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 55 HOLD |
